FRANKFURT: European shares closed slightly lower on Thursday after US President Donald Trump threatened to impose tariffs on alcoholic products from the European Union, further aggravating a ...
The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested the latest economic data and Trump's response to Canada and EU tariffs. The S&P 500 closed in correction territory.
In the most recent trading session, Novo Nordisk (NVO) closed at $75.89, indicating a +1.47% shift from the previous trading day.
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
The pan-European Stoxx 600 edged down 0.2 per cent. Spirit-makers Pernod Ricard and Campari fell 4 per cent and 4.3 percent ...
Zacks Investment Research on MSN11h
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Stan Wong, portfolio manager at Scotia Wealth Management, discusses his past stock picks and how they're doing in the market ...
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Actions The Motley Fool is taking today to navigate uncertainty within its products. A five-part checklist with practical ...
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback